The Fly | XOMA

Over a week ago

Xoma just downgraded at Benchmark, here's why

XOMA

May 22, 11:42 AM

Xoma just downgraded at H.C. Wainwright, here's why

XOMA

Apr 30, 6:06 AM

Ligand price target raised by $25 at Stifel, here's why

Apr 27, 2:05 PM

Ligand price target raised by $10 at BofA, here's why

Apr 27, 1:56 PM

Xoma just downgraded at Lucid Capital, here's why

XOMA

Apr 27, 9:11 AM

Morning Movers: Domino's Pizza sinks following first quarter results

Apr 27, 8:53 AM

Ligand to acquire Xoma for $39.00 per share in cash

Apr 27, 7:22 AM

Ligand to buy Xoma for $39 per share, WSJ reports

Apr 27, 6:30 AM

Xoma reports Q4 EPS 26c, consensus (13c)

XOMA

Mar 18, 6:14 AM

Xoma price target raised by $5 at Leerink

XOMA

Feb 24, 6:08 AM

Xoma announces CFO Burns to step down, Trigilio to succeed

XOMA

Jan 12, 7:50 AM

H.C. Wainwright remains bullish on Xoma following creative Takeda deal

Dec 30, 11:16 AM

Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement

Dec 30, 7:38 AM

Generation Bio price target lowered by $1.50 at Wedbush, here's why

Dec 16, 9:09 AM

Generation Bio downgraded to Hold from Buy at Jefferies

Dec 16, 5:09 AM

Xoma to acquire Generation Bio for $4.2913 per share

Dec 15, 5:04 PM

Xoma to acquire Generation Bio for $4.2913 per share

Dec 15, 5:02 PM

Xoma price target lowered by $7 at H.C. Wainwright, here's why

XOMA

Dec 11, 10:51 AM

Xoma price target lowered by $13 at Leerink, here's why

Dec 11, 9:57 AM

Xoma falls 21% after partner Rezolute announces trial failure

Dec 11, 9:01 AM

Xoma price target lowered by $10 at Lucid Capital, here's why

XOMA

Dec 11, 8:58 AM

Xoma initiated with bullish view at Lucid Capital, here's why

XOMA

Dec 9, 6:45 AM

Xoma announces closing of transaction to acquire Mural Oncology

Dec 5, 9:02 AM

Mural Oncology announces effectiveness of scheme of arrangement

Dec 5, 7:46 AM

Mural Oncology announces final cash consideration payable on acquisition close

Nov 26, 9:04 AM

Diversified Revenue Streams: Xoma benefits from recurring royalty and milestone payments from licensed intellectual property, providing a stable financial foundation.

Strategic Venture Investment Arm: Through Xoma Ventures, the company invests in early-stage biotech, diversifying its portfolio and potential for future returns.

Robust Intellectual Property Portfolio: Decades of innovation have resulted in a substantial collection of patents and proprietary knowledge, particularly in antibody development.

Reliance on Partner Clinical Success: Xoma's revenue generation is heavily dependent on the successful clinical development and regulatory approval of drug candidates by its collaboration partners.

Regulatory Approval Uncertainties: Despite successful clinical trials, there is no guarantee that partner-developed products will receive necessary regulatory approvals from health authorities.

Dependence on Licensee Commercialization: Xoma's royalty revenues are directly tied to the commercial success and sales performance of licensed products by its partners, over which Xoma has limited direct control.

Diversified Revenue Streams: Xoma benefits from recurring royalty and milestone payments from licensed intellectual property, providing a stable financial foundation.

Strategic Venture Investment Arm: Through Xoma Ventures, the company invests in early-stage biotech, diversifying its portfolio and potential for future returns.

Robust Intellectual Property Portfolio: Decades of innovation have resulted in a substantial collection of patents and proprietary knowledge, particularly in antibody development.

Reliance on Partner Clinical Success: Xoma's revenue generation is heavily dependent on the successful clinical development and regulatory approval of drug candidates by its collaboration partners.

Regulatory Approval Uncertainties: Despite successful clinical trials, there is no guarantee that partner-developed products will receive necessary regulatory approvals from health authorities.

Over a week ago

Xoma just downgraded at Benchmark, here's why

XOMA

May 22, 11:42 AM

Xoma just downgraded at H.C. Wainwright, here's why

XOMA

Apr 30, 6:06 AM

Ligand price target raised by $25 at Stifel, here's why

Apr 27, 2:05 PM

Ligand price target raised by $10 at BofA, here's why

Apr 27, 1:56 PM

Xoma just downgraded at Lucid Capital, here's why

XOMA

Apr 27, 9:11 AM

Morning Movers: Domino's Pizza sinks following first quarter results

Apr 27, 8:53 AM

Ligand to acquire Xoma for $39.00 per share in cash

Apr 27, 7:22 AM

Ligand to buy Xoma for $39 per share, WSJ reports

Apr 27, 6:30 AM

Xoma reports Q4 EPS 26c, consensus (13c)

XOMA

Mar 18, 6:14 AM

Xoma price target raised by $5 at Leerink

XOMA

Feb 24, 6:08 AM

Xoma announces CFO Burns to step down, Trigilio to succeed

XOMA

Jan 12, 7:50 AM

H.C. Wainwright remains bullish on Xoma following creative Takeda deal

Dec 30, 11:16 AM

Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement

Dec 30, 7:38 AM

Generation Bio price target lowered by $1.50 at Wedbush, here's why

Dec 16, 9:09 AM

Generation Bio downgraded to Hold from Buy at Jefferies

Dec 16, 5:09 AM

Xoma to acquire Generation Bio for $4.2913 per share

Dec 15, 5:04 PM

Xoma to acquire Generation Bio for $4.2913 per share

Dec 15, 5:02 PM

Xoma price target lowered by $7 at H.C. Wainwright, here's why

XOMA

Dec 11, 10:51 AM

Xoma price target lowered by $13 at Leerink, here's why

Dec 11, 9:57 AM

Xoma falls 21% after partner Rezolute announces trial failure

Dec 11, 9:01 AM

Xoma price target lowered by $10 at Lucid Capital, here's why

XOMA

Dec 11, 8:58 AM

Xoma initiated with bullish view at Lucid Capital, here's why

XOMA

Dec 9, 6:45 AM

Xoma announces closing of transaction to acquire Mural Oncology

Dec 5, 9:02 AM

Mural Oncology announces effectiveness of scheme of arrangement

Dec 5, 7:46 AM

Mural Oncology announces final cash consideration payable on acquisition close

Nov 26, 9:04 AM

Company News

Company News